A research center that will evaluate the use of psychedelic drugs to treat conditions such as addiction, alcoholism and depression was announced by Johns Hopkins University.
“Johns Hopkins is deeply committed to exploring innovative treatments for our patients,” Paul Rothman, dean of the medical faculty and CEO of Johns Hopkins Medicine, said in a statement.
“Our scientists have shown that psychedelics have real potential as medicine, and this new center will help us find that potential,” Rothman added.
The center, which received $17 million in funding from a group a private donors, will also use psychedelic drugs to study the brain and behavior.
That also means that the center will research the medical benefits of psychedelics. The center has already said its researchers will study psilocybin, the chemical naturally found in “magic mushrooms,” and see whether the compound helps with things like opioid addiction, Alzheimer’s disease, post-traumatic stress disorder, post-treatment Lyme disease, anorexia and alcohol use in people with major depression.